PharmaShots | Incisive News in 3 Shots

Subscribe Now

Oportuzumab monatox

The US FDA Rejects Sesen Bio's Vicineum (oportuzumab monatox-qqrs) for the Treatment of BCG-Unresponsive NMIBC

The US FDA Rejects Sesen Bio's Vicineum (oportuzumab monatox-qqrs) for the Treatment of BCG-Unresponsive NMIBC

August 16, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us